Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

SurModics bolsters drug delivery IP; reports strong FY08

This article was originally published in Clinica

Executive Summary

SurModics has strengthened its drug delivery business after purchasing certain IP assets from PR Pharmaceuticals (PRP), a Fort Collins, Colorado-based specialist in injectable, biodegradable, sustained-release formulations. SurModics will gain PRP's protein delivery capabilities and its know-how in delivering injectable microparticles through smaller-gauge needles. The latter is used in ophthalmic applications – an area in which SurModics is particularly – as well as in subcutaneous or intramuscular injections. In addition to the IP, Eden Prairie, Minnesota-based SurModics will also take over several customer-paid development projects from PRP, as well as be a paid development partner for PRP's proprietary basal insulin product InsuLAR.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT043372

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel